Get the Stockscreener App
17.70
1.28%
-0.23
After Hours:
17.65
-0.05
-0.28%
Adma Biologics Inc stock is traded at $17.70, with a volume of 2.89M.
It is down -1.28% in the last 24 hours and down -10.52% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$17.93
Open:
$17.94
24h Volume:
2.89M
Relative Volume:
0.94
Market Cap:
$4.21B
Revenue:
$474.17M
Net Income/Loss:
$208.93M
P/E Ratio:
20.84
EPS:
0.8493
Net Cash Flow:
$65.61M
1W Performance:
-3.49%
1M Performance:
-10.52%
6M Performance:
-4.38%
1Y Performance:
+7.34%
1-Day Range:
$17.47
$18.33
1-Week Range:
$16.24
$18.95
52-Week Range:
$13.76
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
17.70 | 4.27B | 474.17M | 208.93M | 65.61M | 0.8493 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - sharewise.com
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? - sharewise.com
Breakout Zone: Whats the beta of ADMA Biologics Inc stock2025 Key Lessons & Safe Entry Momentum Stock Tips - baoquankhu1.vn
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook - Finviz
How ADMA’s Multi‑Year Revenue Targets And Margin Push At ADMA Biologics (ADMA) Has Changed Its Investment Story - Yahoo Finance
A Look At ADMA Biologics (ADMA) Valuation After Raised Guidance And New Long Term Growth Targets - Yahoo Finance
ADMA Biologics Highlights $510M+ 2025 Revenue, Raises 2027 Outlook at JPM Healthcare Conference - Yahoo Finance
Is ADMA Biologics (ADMA) Still Attractive After Recent Share Price Pullback - Yahoo Finance
ADMA Biologics Updates 2025, 2026 Revenue Outlook; 2027 Guidance Issued - marketscreener.com
ADMA Biologics (ADMA) Projects Strong Revenue Growth Through 202 - GuruFocus
ADMA Projects Strong Growth Momentum Heading Into 2026 - GuruFocus
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides ... - Bluefield Daily Telegraph
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update - GlobeNewswire
ADMA Biologics Inc (ADMA) Investor Outlook: Exploring a 42.99% Potential Upside in Biotech - DirectorsTalk Interviews
Adma Biologics raises FY25 revenue view to at least $510M from at least $500M - MSN
Can ADMA Biologics Inc. stock beat analyst upgrades2025 Earnings Impact & Proven Capital Preservation Tips - ulpravda.ru
Will ADMA Biologics Inc. stock gain from lower inflationWeekly Trade Report & Risk Managed Investment Entry Signals - ulpravda.ru
ADMA Biologics IncCommon Stock (NQ:ADMA) - FinancialContent
What momentum indicators show for ADMA Biologics Inc. stock2025 Momentum Check & Weekly High Return Opportunities - ulpravda.ru
Bear Alert: Can ADMA Biologics Inc. stock sustain free cash flow growth2025 Macro Impact & Daily Risk Controlled Trade Plans - ulpravda.ru
How ADMA Biologics Inc. stock valuations compare to rivalsDividend Cut Warnings & Fast Profit Trading Tips - Улправда
Published on: 2026-01-07 18:06:07 - ulpravda.ru
Nicholas Investment Partners, LP's ADMA Biologics Inc(ADMA) Holding History - GuruFocus
2026 world cup team news comparison: Will ADMA Biologics Inc. stock outperform growth indexes2026 world cup usa national team semifinals goalkeepers counter attacking tactical prediction preview - ulpravda.ru
Why Adma Biologics (ADMA) Outpaced the Stock Market Today - Yahoo Finance
A Look At ADMA Biologics (ADMA) Valuation As J.P. Morgan Healthcare Conference Presentation Nears - Sahm
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026 - The Manila Times
Why (ADMA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Allspring Global Investments Holdings LLC Sells 1,772,112 Shares of ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc $ADMA Shares Sold by Calamos Advisors LLC - MarketBeat
Does Kizi Apparels Limited Have a Competitive Advantage in Its SectorREITs Market Trends & Free Popular Stock Picks Selection - earlytimes.in
ADMA Biologics Earnings Notes - Trefis
ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade - ts2.tech
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Motley Fool
Harbor Capital Advisors Inc. Buys Shares of 59,801 ADMA Biologics Inc $ADMA - MarketBeat
Rice Hall James & Associates LLC Has $4.75 Million Stake in ADMA Biologics Inc $ADMA - MarketBeat
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet - MSN
(ADMA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
High Growth Tech Stocks To Watch In US December 2025 - simplywall.st
The Bull Case For ADMA Biologics (ADMA) Could Change Following Its Higher 2025 Revenue Outlook Revision - Sahm
Adma Biologics Receives Upgraded Price Target on Strong Outlook - AD HOC NEWS
Assessing ADMA Biologics (ADMA) Valuation After Its Upgraded 2025 Revenue Guidance - Sahm
ADMA Biologics (ADMA): Firm updates 2025 revenue guidance - MSN
ADMA Biologics Inc $ADMA Shares Bought by Voya Investment Management LLC - MarketBeat
Texas Permanent School Fund Corp Has $1.87 Million Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance - Finviz
Should You Be Adding ADMA Biologics (NASDAQ:ADMA) To Your Watchlist Today? - Yahoo Finance
Fed Meeting: Will ADMA Biologics Inc. stock outperform growth indexes2025 Pullback Review & Long-Term Growth Stock Strategies - Улправда
Published on: 2025-12-21 05:20:22 - Улправда
Perpetual Ltd Cuts Stake in ADMA Biologics Inc $ADMA - MarketBeat
Jobs Data: How ADMA Biologics Inc. stock valuations compare to rivalsPortfolio Gains Report & Advanced Technical Analysis Signals - Улправда
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.73%
2.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):